Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31955850.
- Also identified by DOI 10.1016/j.cell.2019.11.031 and PMC identifier 7319047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New biological tools provide new techniques to probe fundamental biological processes. Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concentrations at a post-translational level by co-opting the ubiquitin-proteasome system. We describe the PROTAC technology and its application to drug discovery and provide examples where PROTACs have enabled novel biological insights. Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues associated with PROTACs. Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.
Medical subject headings
- Drug Discovery
- Proteasome Endopeptidase Complex
- Proteolysis
- Ubiquitin-Protein Ligases